HTATSF1 and breast neoplasm: Taken together, these results support the argument that a hyperactivated CK2–HTATSF1–TOPBP1 axis confers poor responsiveness of breast tumors to chemotherapeutic agents and that loss of HTATSF1 renders breast tumors more vulnerable to cisplatin treatment.